Esophageal cast (desquamative esophagitis).

Abdom Radiol (NY)

Department of Radiology, University of Vermont Medical Center, 111 Colchester Ave, Burlington, VT, 05401, USA.

Published: October 2021

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00261-021-03174-wDOI Listing

Publication Analysis

Top Keywords

esophageal cast
4
cast desquamative
4
desquamative esophagitis
4
esophageal
1
desquamative
1
esophagitis
1

Similar Publications

Spatial Isoforms Reveal the Mechanisms of Metastasis.

Adv Sci (Weinh)

November 2024

State Key Laboratory of Molecular Oncology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.

In esophageal squamous cell carcinoma (ESCC), lymph node (LN) metastasis is associated with poor survival. Emerging evidence has demonstrated elevated CD8 T-cell levels in metastatic LNs following immunotherapy and increased chemoresistance. However, the underlying regulatory mechanisms of CD8 T cells in chemoresistant/metastatic patients have not been elucidated.

View Article and Find Full Text PDF

Background: Esophageal squamous cell carcinoma (ESCC) is a deadly cancer with no clinically ideal biomarkers for early diagnosis. The objective of this study was to develop and validate a user-friendly diagnostic tool for early ESCC detection.

Methods: The study encompassed three phases: discovery, verification, and validation, comprising a total of 1309 individuals.

View Article and Find Full Text PDF

Leaflet thrombosis is usually an incidental finding and Cardiac CT is the gold standard for its diagnosis, but the classic features of hypoattenuation leaflet thickening (HALT) and hypoattenuation affecting motion (HAM) can also be seen on echocardiography and more specifically on trans-esophageal echocardiography. We describe a case of transcatheter aortic valve thrombosis where both the diagnosis and treatment were based exclusively on the echocardiographic evaluation, without the need of cardiac CT, with good outcome for the patient.

View Article and Find Full Text PDF
Article Synopsis
  • Poliprotect (a mucosal protective agent) was found to be just as effective as omeprazole for treating heartburn and epigastric pain in patients without visible esophageal damage.
  • In a 4-week study, 275 participants were treated with either omeprazole or Poliprotect, with Poliprotect showing similar symptom relief and no significant changes in gut microbiota.
  • No serious side effects occurred in either treatment group, suggesting Poliprotect is a safe alternative for patients who cannot take proton-pump inhibitors like omeprazole.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!